BioSpace News Archive

BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment.

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft.

etherna, a leading mRNA/LNP technologies company, announced that Bernard Sagaert has been confirmed-as Chief Executive Officer.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its third quarter 2023 financial results before the market opens on Friday, November 3, 2023.

Cognito Therapeutics announced the appointment of Greg Weaver as Chief Financial Officer, to lead all finance-related and investor relations functions at the Company.

Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company based in Chicago, announced it has joined the Biosimilars Forum, a growing coalition of companies that work together to make safe, effective and lower-cost biosimilars accessible to the patients that need them.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan® for reduction in risk of overt hepatic encephalopathy recurrence in adults.

Evidation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to fund the 2023 Influenza-like Illness Detect & Protect Studies.

Global genomics solutions provider Integrated DNA Technologies, an operating company in the Life Sciences segment of Danaher Corporation, announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa.

Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”) will present data showcasing the continuous progress and innovation generated by the Company’s cutting-edge LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society (OTS).